Replimune (REPL) Current Leases (2019 - 2026)
Replimune (REPL) posted Current Leases of $1.2 million for Q1 2026, down 4.53% sequentially from $1.2 million in Q4 2025, and down 2.2% YoY from $1.2 million in Q1 2025.
Analysis
Replimune (REPL) Current Leases (2019 - 2026) Analysis & Trends
Replimune has reported Current Leases for 8 years, with the latest figure at $1.2 million in Q1 2026.
- Quarterly Current Leases fell 2.2% year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.2 million (down 2.2% YoY) and the FY2026 annual result came in at $1.2 million, down 2.2% from the prior year.
- Current Leases declined to $1.2 million in Q1 2026 per REPL's latest filing, from $1.2 million in the prior quarter.
- Over five years, Current Leases peaked at $2.8 million in Q3 2025 and troughed at $1.0 million in Q3 2022.
- A 5-year average of $1.9 million and a median of $1.2 million in 2025 frame the typical range for Current Leases.
- The sharpest annual moves came in 2022 and 2023: Current Leases tumbled 59.14% in 2022, then jumped 167.27% in 2023.
- Over 5 years, Current Leases stood at $1.0 million in 2022, then advanced by 11.93% to $1.2 million in 2023, then increased by 0.09% to $1.2 million in 2024, then rose by 4.21% to $1.2 million in 2025, then decreased by 4.53% to $1.2 million in 2026.
- According to Business Quant data, Current Leases over the past three periods registered $1.2 million, $1.2 million, and $2.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 11.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 16.75 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 21.95 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 45.93 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.27 Mn |
| 10 | Replimune | 1.46 Bn | 1.46 Bn | - | 2.90 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.90 Mn |
| Mar 31, 2026 | 2.88 Mn |
| Dec 31, 2025 | 2.86 Mn |
| Sep 30, 2025 | 2.84 Mn |
| Jun 30, 2025 | 2.82 Mn |
| Mar 31, 2025 | 2.80 Mn |
| Dec 31, 2024 | 2.78 Mn |
| Sep 30, 2024 | 2.76 Mn |
| Jun 30, 2024 | 2.74 Mn |
| Mar 31, 2024 | 2.72 Mn |
| Dec 31, 2023 | 2.70 Mn |
| Sep 30, 2023 | 2.68 Mn |
| Jun 30, 2023 | 2.66 Mn |
| Mar 31, 2023 | 2.64 Mn |
| Dec 31, 2022 | 2.62 Mn |
| Sep 30, 2022 | 2.60 Mn |
| Jun 30, 2022 | 2.58 Mn |
| Mar 31, 2022 | 2.56 Mn |
| Dec 31, 2021 | 2.54 Mn |
| Sep 30, 2021 | 2.52 Mn |